Furthermore, the study should put more effort to define the effective range within which ERBB2 inhibition can generate an antileukemic effect and find solutions to drug resistance caused by aberrant HOX-network gene expressions in AML. This evidence concerns the gene ERBB2 and acute myeloid leukemia.